Table 1.
Zones of Inhibition formed by clinical isolates against different tested antibiotic disks.
| Pathogens | AMC | CRO | FOX | FEP | CAZ | CTX | ATM | CT | IPM | AMP | VA | MH | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zones of inhibition (mm) | |||||||||||||
| MRSA | 18 | – | – | – | – | – | – | – | 17 | 15 | 20 | 20 | |
| Klebsiella pneumoniae | – | – | – | – | – | – | – | 15 | 23 | – | – | 15 | |
| Escherichia coli | – | – | 24∗ | 16∗ | 19∗ | – | 15 | 14 | 28 | – | – | 18 | |
| Pseudomonas aeruginosa | – | – | – | – | – | – | – | 16 | 12 | – | – | – | |
| Listeria monocytogenes (ATCC 13932) | 30 | 29 | 26 | 29 | 29 | 30 | 33 | 15 | 30 | 25 | – | 16 | |
Where Augmentin (AMC), Ceftriaxone (CRO), Cefoxitin (FOX) Cefepime (FEP), Ceftazidime (CAZ), Cefotaxime (CTX), Aztreonam (ATM), Colistin (CT), Imipenem (IPM), Ampicillin (AMP), Vancomycin (VA), and Minocycline (MH). ESBL phenomenon exhibited by increase in zone of inhibition. Whereas (–) means ‘no zone of inhibition.
∗indicates ESBL phenomenon marked by increase in zone of inhibition caused by AMC and cephalosporin discs.